drugset / Trial / NCT06968481
Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage
RandomizedParallel-groupOpen-labelPrevention
Summary
An open-label, randomized, single-center, dose ascending trial will be conducted to evaluate the efficacy and safety of sublingual oxytocin for the prevention of post-partum hemorrhage caused by uterine atony in term pregnant women having an uncomplicated vaginal delivery.
Timeline
- Start
- 2026-05-30
- Primary completion
- 2026-10-30
- Completion
- 2026-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxytocin | Peptide | 10 iu | Other |
| Subject | Oxytocin | Peptide | 1000 iu | Other |
| Subject | Oxytocin | Peptide | 3000 iu | Other |
| Subject | Oxytocin | Peptide | 6000 iu | Other |
Indications
No indication recorded.